ERASCA INC
NASDAQ: ERAS (Erasca, Inc.)
Kemas kini terakhir: semalam, 6:52PM9.96
-0.33 (-3.21%)
| Penutupan Terdahulu | 10.29 |
| Buka | 10.29 |
| Jumlah Dagangan | 6,201,107 |
| Purata Dagangan (3B) | 4,198,904 |
| Modal Pasaran | 2,825,769,728 |
| Harga / Buku (P/B) | 7.85 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 12 Nov 2025 |
| EPS Cair (TTM) | -0.570 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 12.72% |
| Nisbah Semasa (MRQ) | 12.35 |
| Aliran Tunai Operasi (OCF TTM) | -107.72 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -91.89 M |
| Pulangan Atas Aset (ROA TTM) | -22.16% |
| Pulangan Atas Ekuiti (ROE TTM) | -45.82% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Erasca, Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | -1.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -5.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | 4.0 |
| Purata | 0.00 |
|
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 11.69% |
| % Dimiliki oleh Institusi | 84.38% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Frazier Life Sciences Management, L.P. | 30 Sep 2025 | 22,729,436 |
| Logos Global Management Lp | 30 Sep 2025 | 15,150,000 |
| Arch Venture Management, Llc | 30 Sep 2025 | 11,055,554 |
| Affinity Asset Advisors, Llc | 30 Sep 2025 | 4,285,787 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 11.00 (Piper Sandler, 10.44%) | Beli |
| 11.00 (HC Wainwright & Co., 10.44%) | Beli | |
| Median | 8.00 (-19.68%) | |
| Rendah | 5.00 (Mizuho, -49.80%) | Beli |
| 5.00 (Guggenheim, -49.80%) | Beli | |
| Purata | 8.00 (-19.68%) | |
| Jumlah | 4 Beli | |
| Harga Purata @ Panggilan | 5.75 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Piper Sandler | 16 Jan 2026 | 11.00 (10.44%) | Beli | 9.62 |
| 07 Jan 2026 | 5.00 (-49.80%) | Beli | 5.17 | |
| HC Wainwright & Co. | 13 Jan 2026 | 11.00 (10.44%) | Beli | 7.51 |
| Mizuho | 09 Dec 2025 | 5.00 (-49.80%) | Beli | 3.30 |
| Guggenheim | 14 Nov 2025 | 5.00 (-49.80%) | Beli | 2.58 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 21 Jan 2026 | Pengumuman | Erasca Announces Pricing of Upsized Public Offering of Common Stock |
| 20 Jan 2026 | Pengumuman | Erasca Announces Proposed Public Offering of $150 Million of Common Stock |
| 14 Jan 2026 | Pengumuman | Precision Killers: Why Big Pharma is Betting Billions to Beat a $170B Patent Cliff |
| 12 Jan 2026 | Pengumuman | Erasca Announces Promising Early Clinical Data for ERAS-0015 and 2026-2027 Milestones |
| 06 Jan 2026 | Pengumuman | Erasca to Present at the 44th Annual J.P. Morgan Healthcare Conference |
| 11 Dec 2025 | Pengumuman | Platform Technologies Drive $211B Surge in Precision Cancer Treatment |
| 25 Nov 2025 | Pengumuman | Erasca to Present at the 8th Annual Evercore Healthcare Conference |
| 12 Nov 2025 | Pengumuman | Erasca Reports Third Quarter 2025 Business Updates and Financial Results |
| 06 Nov 2025 | Pengumuman | Erasca Announces Issuance of a U.S. Patent Covering Pan-RAS Molecular Glue ERAS-0015 |
| 04 Nov 2025 | Pengumuman | Erasca to Present at Upcoming Conferences in November |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |